Roger Stupp

TL;DR: Neoadjuvant docetaxel–cisplatin was effective and tolerable in stage IIIA pN2 NSCLC, with chemotherapy contributing significantly to outcomes.

TL;DR: VRL oral was developed as a line extension of VRL IV on the basis that similar AUCs result in similar activities, and bioequivalence tests were performed to support this calculation.

TL;DR: Molecular studies suggest a strong predictive role of the DNA repair enzyme O6-methyl-guanine-DNA- methyl-transferase (MGMT) and outcome of TMZbased chemotherapy and this review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment.

TL;DR: In elderly glioblastoma patients, the NOA-08 and the Nordic trial of RT alone versus temozolomide alone demonstrated a profound impact of MGMT promoter methylation on outcome by therapy and thus established MGMT as a predictive biomarker in this patient population.

TL;DR: Combining capecitabine and oxaliplatin yields promising activity in advanced colorectal cancer, with the main toxicity is diarrhea, which is manageable with appropriate dose reductions.